重组人血小板生成素联合糖皮质激素和环胞素A治疗免疫性血小板减少症的研究

Recombinant human thrombopoietin combined with corticosteroids and cyclosporine A treatment reduced the effect of disease of immune platelet

目的:探讨重组人血小板生成素、糖皮质激素及环孢素A联合应用治疗免疫性血小板减少性紫癜的疗效。方法:选取75例免疫性血小板减少性紫癜患者,均给予重组人血小板生成素、糖皮质激素及环孢素A治疗,对比治疗前、后血小板(PLT)、白细胞数(WBC)及血红蛋白(Hb)变化情况以及治疗总有效率。结果:治疗前PLT、WBC及Hb分别为(14.41±2.11)×109/L、(8.92±1.01)×109/L及(119.32±9.8)g/L,治疗后分别为(118.92±14.50)×109/L、(9.01±1.05)×109/L及(120.14±6.84)g/L,治疗后血小板数显著高于治疗前,其差异有统计学意义(t=61.769,P<0.001)。治疗前、后WBC、Hb比较无统计学意义(t=0.535,t=0.594;P>0.05)。治疗总有效率为89.3%(67/75),不良反应率为4.0%。结论:联合应用重组人血小板生成素、糖皮质激素及环孢素A治疗ITP的疗效佳,能显著提高血小板数,值得推广。

Objective： To investigate the recombinant human thrombopoietin, corticosteroids, cyclosporin A combined therapy to reduce purpura 75 cases of immune thrombocytopenic. Methods： From 2011 March to 2014 January in our hospital were treated with immune thrombocytopenic purpura patients a total of 75 cases, were given the treatment of thrombopoietin, corticosteroids, cyclosporin A recombinant human, compared before and after treatment （platelet）, PLT （WBC）, WBC （hemoglobin） Hb changes and the total curative effect of therapy. Results：Before treatment, PLT, WBC, Hb were （14.41＋2.11）×10^9/L, （8.92＋1.01）×10^9/L, （119.32＋9.8）g/L, respectively after treatment for （118.92＋14.50）×10^9/L, （9.01＋1.05）×10^9/L, （120.14＋6.84） g/L, the number of platelet therapy significantly higher than before treatment （t=61.769, P=0.000）, WBC, Hb before and after treatment showed no statistical significance （t=0.535, P=0.593;t=0.594, P=0.0553）. The total curative effect in the treatment of treatment was 89.3%（67/75）, the rate of adverse reaction was 4%. Conclusion：The combined application of recombinant human thrombopoietin, corticosteroids, cyclosporin A in the treatment of ITP curative effect is good, significantly improve the platelet count, worthy of promotion.